OCTOBER 2024: Loma engages with key stakeholders in Kenya. We are thrilled to share highlights from our recent visit to Kenya, where our team had the privilege of meeting with influential local stakeholders to discuss our work on developing a therapeutic vaccine for...
SEPTEMBER 2024: Loma presents at Nordic Life Science Days 2024. Loma participated in Nordic Life Science (NLS) Days 2024, where we had the opportunity to present our pioneering work on developing a therapeutic vaccine against HPV+ cancers. Engaging with life science...
SEPTEMBER 2024: Loma joins the Venture House Program at BII. We are thrilled to announce that Loma has been selected to join the Venture House program at the BioInnovation Institute (BII)! This opportunity marks a significant milestone in our mission to develop the...
September 2024: Loma selected for the Women TechEU Program. We are honored to announce that Loma has been selected as a recipient of the Women TechEU grant, a prestigious program by the European Commission that supports female-led deep-tech startups in Europe. This...
Human ex vivo validation of the potential of Loma’s HPV-targeted immunotherapy has been published in Cancers. The study conducted in collaboration between Loma Therapeutics and Hervolution supports that Loma’s unique immunotherapy can induce strong and functional CD8+...
